A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial - Concepedia

Concepedia

Publication | Open Access

A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial

DOI Full Paper Access

21

Citations

16

References

2010

Year

Benjamin Young, Thanes Vanig, Edwin DeJesus, Trevor Hawkins, Marty St. Clair, Linda Yau, Belinda Ha

HIV Clinical Trials

Abstract

in this pilot study, abacavir/lamivudine plus raltegravir was effective and generally well-tolerated over 48 weeks with modest changes in fasting lipids.

References

	Year	Citations

Page 1